Literature DB >> 22404725

Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study.

K A Forde1, K Haynes, A B Troxel, S Trooskin, M T Osterman, S E Kimmel, J D Lewis, V Lo Re.   

Abstract

Hepatitis C virus (HCV) infection is associated with systemic inflammation and metabolic complications that might predispose patients to atherosclerosis. However, it remains unclear if HCV infection increases the risk of acute myocardial infarction (MI). To determine whether HCV infection is an independent risk factor for acute MI among adults followed in general practices in the United Kingdom (UK), a retrospective cohort study was conducted in The Health Improvement Network, from 1996 through 2008. Patients ≥18 years of age with at least 6 months of follow-up and without a prior history of MI were eligible for study inclusion. HCV-infected individuals, identified with previously validated HCV diagnostic codes (n = 4809), were matched on age, sex and practice with up to 15 randomly selected patients without HCV (n = 71 668). Rates of incident MI among patients with and without a diagnosis of HCV infection were calculated. Adjusted hazard ratios were estimated using Cox proportional hazards regression, controlling for established cardiovascular risk factors. During a median follow-up of 3.2 years, there was no difference in the incidence rates of MI between HCV-infected and -uninfected patients (1.02 vs 0.92 events per 1000 person-years; P = 0.7). HCV infection was not associated with an increased risk of incident MI (adjusted HR, 1.10; 95% confidence interval [CI], 0.67-1.83). Sensitivity analyses including the exploration of a composite outcome of acute MI and coronary interventions yielded similar results (adjusted HR, 1.16; 95% CI, 0.77-1.74). In conclusion, HCV infection was not associated with an increased risk of incident MI.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 22404725      PMCID: PMC3636529          DOI: 10.1111/j.1365-2893.2011.01545.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  45 in total

1.  Hepatitis C virus and atherosclerosis in patients with type 2 diabetes.

Authors:  Michiaki Fukui; Yoshihiro Kitagawa; Naoto Nakamura; Toshikazu Yoshikawa
Journal:  JAMA       Date:  2003-03-12       Impact factor: 56.272

2.  Use of the UK General Practice Research Database for pharmacoepidemiology.

Authors:  L A García Rodríguez; S Pérez Gutthann
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

3.  Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research.

Authors:  James D Lewis; Rita Schinnar; Warren B Bilker; Xingmei Wang; Brian L Strom
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-04       Impact factor: 2.890

Review 4.  The immune response in atherosclerosis: a double-edged sword.

Authors:  Göran K Hansson; Peter Libby
Journal:  Nat Rev Immunol       Date:  2006-06-16       Impact factor: 53.106

5.  High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors.

Authors:  I D del Rincón; K Williams; M P Stern; G L Freeman; A Escalante
Journal:  Arthritis Rheum       Date:  2001-12

6.  Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States.

Authors:  S H Mehta; F L Brancati; M S Sulkowski; S A Strathdee; M Szklo; D L Thomas
Journal:  Ann Intern Med       Date:  2000-10-17       Impact factor: 25.391

7.  Determining the predictive value of Read/OXMIS codes to identify incident acute myocardial infarction in the General Practice Research Database.

Authors:  Tarek A Hammad; Mara A McAdams; Andrea Feight; Solomon Iyasu; Gerald J Dal Pan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-12       Impact factor: 2.890

8.  Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection.

Authors:  Adeel A Butt; Shawn L Fultz; C Kent Kwoh; David Kelley; Melissa Skanderson; Amy C Justice
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

9.  Hepatitis C virus infection and the risk of coronary disease.

Authors:  Adeel A Butt; Wang Xiaoqiang; Matthew Budoff; David Leaf; Lewis H Kuller; Amy C Justice
Journal:  Clin Infect Dis       Date:  2009-07-15       Impact factor: 9.079

10.  Association between hepatitis C virus core protein and carotid atherosclerosis.

Authors:  Yuko Ishizaka; Nobukazu Ishizaka; Eiko Takahashi; Tadao Unuma; Ei-ichi Tooda; Hideki Hashimoto; Ryozo Nagai; Minoru Yamakado
Journal:  Circ J       Date:  2003-01       Impact factor: 2.993

View more
  22 in total

Review 1.  Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.

Authors:  Umberto Vespasiani-Gentilucci; Paolo Gallo; Antonio De Vincentis; Giovanni Galati; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

2.  Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study.

Authors:  Matteo Nicola Dario Di Minno; Pasquale Ambrosino; Antonio Riccardo Buonomo; Biagio Pinchera; Ilenia Calcaterra; Manuel Crispo; Riccardo Scotto; Francesco Borgia; Consalvo Mattia; Ivan Gentile
Journal:  Intern Emerg Med       Date:  2019-08-08       Impact factor: 3.397

3.  Metabolic Manifestations and Complications Associated With Chronic Hepatitis C Virus Infection.

Authors:  Robert J Wong; Robert G Gish
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-05

Review 4.  Assessing cardiovascular risk in hepatitis C: An unmet need.

Authors:  Javier Ampuero; Manuel Romero-Gómez
Journal:  World J Hepatol       Date:  2015-09-08

5.  Hepatitis C virus G1b infection decreases the number of small low-density lipoprotein particles.

Authors:  Chika Kinoshita; Tomohisa Nagano; Nobuyoshi Seki; Yoichi Tomita; Tomonori Sugita; Yuta Aida; Munenori Itagaki; Kenichi Satoh; Satoshi Sutoh; Hiroshi Abe; Akihito Tsubota; Yoshio Aizawa
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

Review 6.  Hepatitis C virus infection and coronary artery disease risk: a systematic review of the literature.

Authors:  Robert J Wong; Fasiha Kanwal; Zobair M Younossi; Aijaz Ahmed
Journal:  Dig Dis Sci       Date:  2014-06-04       Impact factor: 3.199

7.  Influence of Diabetes on Circulating Apoptotic Microparticles in Patients with Chronic Hepatitis C.

Authors:  Jolanta Zuwala-Jagiello; Monika Pazgan-Simon; Eugenia Murawska-Cialowicz; Krzysztof Simon
Journal:  In Vivo       Date:  2017 Sep-Oct       Impact factor: 2.155

Review 8.  Metabolic alterations and hepatitis C: From bench to bedside.

Authors:  Ming-Ling Chang
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

9.  Association Between Chronic Hepatitis C Virus Infection and Myocardial Infarction Among People Living With HIV in the United States.

Authors:  Jessica Williams-Nguyen; Stephen E Hawes; Robin M Nance; Sara Lindström; Susan R Heckbert; H Nina Kim; W Chris Mathews; Edward R Cachay; Matt Budoff; Christopher B Hurt; Peter W Hunt; Elvin Geng; Richard D Moore; Michael J Mugavero; Inga Peter; Mari M Kitahata; Michael S Saag; Heidi M Crane; Joseph A Delaney
Journal:  Am J Epidemiol       Date:  2020-06-01       Impact factor: 4.897

Review 10.  Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms.

Authors:  Luigi E Adinolfi; Rosa Zampino; Luciano Restivo; Amedeo Lonardo; Barbara Guerrera; Aldo Marrone; Fabio Nascimbeni; Anna Florio; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.